Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Development of a gemcitabine-loaded microbubble carrier for treatment of pancreatic ductal adenocarcinoma
FY 2023-24
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a serious cancer with a low chance of survival. Its main drug used for treatment, gemcitabine, has side effects because it needs to be given in high doses. Scientists have tried using microscopic bubbles and sound waves to deliver the drug more precisely to the tumour, but this has not solved its toxicity issues. Our goal is to make a safe and effective treatment for PDAC, intended for clinical use. This research will develop a new strategy for low dose, local delivery of gemcitabine to PDACs by loading the drug directly into bubbles that can be non-invasively triggered to release its drug payload by focused ultrasound. Direct loading of drug into bubbles will allow us to administer less drug to decrease side effects. This agent will be tested using mouse models with pancreatic tumours. We will use Health Canada-approved materials to expedite the translation of this new agent to patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506147
Name
Khan Osama
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a gemcitabine-loaded microbubble carrier for treatment of pancreatic ductal adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Advanced Pancreatic Cancer; Cavitation; Drug Delivery; Focused Ultrasound; Gemcitabine; Microbubble; Pancreas; Pancreatic Ductal Adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a serious cancer with a low chance of survival. Its main drug used for treatment, gemcitabine, has side effects because it needs to be given in high doses. Scientists have tried using microscopic bubbles and sound waves to deliver the drug more precisely to the tumour, but this has not solved its toxicity issues. Our goal is to make a safe and effective treatment for PDAC, intended for clinical use. This research will develop a new strategy for low dose, local delivery of gemcitabine to PDACs by loading the drug directly into bubbles that can be non-invasively triggered to release its drug payload by focused ultrasound. Direct loading of drug into bubbles will allow us to administer less drug to decrease side effects. This agent will be tested using mouse models with pancreatic tumours. We will use Health Canada-approved materials to expedite the translation of this new agent to patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khan, Osama
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~